Final Clinical Study Report
Protocol B3451002
CLINICAL STUDY REPORT SYNOPSIS
Vaccine Name and Compound Number: Staphylococcus aureus 4-Antigen Vaccine,Compound Number: PF-06290510
Report Title: Final Report: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled
Study to Evaluate the Safety and Efficacy of Staphylococcus Aureus 4 Antigen Vaccine(SA4Ag) in Adults Undergoing Elective Open Posterior Spinal Fusion Procedures With
Multilevel Instrumentation
Protocol Number: B3451002
Sponsor: Pfizer, Inc.
Phase of Development: Phase 2b
First Subject First Visit: 02 July 2015
Last Subject Last Visit: 27 June 2019
Serology Completion Date: 23 August 2019
Coordinating Investigator(s):University of Virginia Health System
1215 Lee St, SW
Charlottesville, VA 22903
United States
Refer to Appendix 16.1.4.1 for a list of investigators involved in this study.
Study Center(s): This study was undertaken by Pfizer and conducted at 138 sites in Austria,
Bulgaria, Canada, France, Germany, Hungary, Japan, Romania, Spain, Sweden, the United
Kingdom, and the United States, including 9 that were shipped investigational product but
did not enroll any subjects. Refer to Appendix 16.1.4.1 for a list of sites involved in thisstudy.
Date of Current Version: 30 April 2020
Date(s) of Previous Report(s): Not applicable.

PFIZER CONFIDENTIAL
Page 1

Final Clinical Study Report
Protocol B3451002
CLINICAL STUDY REPORT SYNOPSISOBJECTIVES
Study Objectives and Endpoints:
Table S1. Study Objectives and Endpoints
Objective
Primary Efficacy
 To assess the efficacy of SA4Ag in
the prevention of postoperative
Staphylococcus aureus BSIa and/or deep
incisional or organ/space SSIb occurring
within 90 days of elective open posterior
spinal fusion procedures with multilevel
instrumentation, in adults aged 18 to<86 years.
Primary Safety
 To describe the safety and tolerability of asingle vaccination of SA4Ag in adults
aged 18 to <86 years undergoing elective
open posterior spinal fusion procedureswith multilevel instrumentation, by
measuring local reactions, systemic events,
and AEs.

Endpoint

The number of subjects in each vaccine group withpostoperative S aureus BSI and/or deep incisional ororgan/space SSI occurring within 90 days of elective
open posterior spinal fusion procedures withmultilevel instrumentation, as confirmed by the EAC.



Number and proportion of subjects in each vaccine
group with local reactions (redness, swelling, andpain) occurring within the 10-day period following
study vaccination.



Number and proportion of subjects in each vaccine
group with systemic events (fever, fatigue, headache,vomiting, diarrhea, muscle, or joint pain) occurring
within the 10-day period following study vaccination.



Number and proportion of subjects in each vaccine
group with AEs reported during the following time
periods:

From vaccination until the day of surgery

From vaccination until the Day 42 postoperativeevaluation



From the day of surgery until the Day 42
postoperative evaluation



From the Day 42 postoperative evaluation until
the Day 180 postoperative evaluation (newly
diagnosed chronic medical disorders)Number and proportion of subjects in each vaccine
group with SAEs reported during the following time
periods:


From vaccination until the Day 180 postoperativeevaluation

PFIZER CONFIDENTIAL
Page 2Final Clinical Study Report
Protocol B3451002
CLINICAL STUDY REPORT SYNOPSIS
Table S1. Study Objectives and Endpoints
Objective

Endpoint

Secondary Efficacy
 To assess the efficacy of SA4Ag in theprevention of postoperative S aureus BSI
and/or deep incisional or organ/space SSI
occurring within 180 days of elective open
posterior spinal fusion procedures withmultilevel instrumentation, in adults
18 to <86 years of age.

From vaccination until the day of surgery

From the day of surgery until the Day 180
postoperative evaluation



The number of subjects in each vaccine group withpostoperative S aureus BSI and/or deep incisional ororgan/space SSI occurring within 180 days of elective
open posterior spinal fusion procedures withmultilevel instrumentation.

To assess the efficacy of SA4Ag in theprevention of postoperative S aureus SSI
occurring within 90 days of elective open
posterior spinal fusion procedures withmultilevel instrumentation, in adults 18 to<86 years of age.

The number of subjects in each vaccine group withpostoperative S aureus SSI occurring within 90 daysof elective open posterior spinal fusion procedureswith multilevel instrumentation.

To assess the efficacy of SA4Ag in theprevention of postoperative S aureus SSI
occurring within 180 days of elective open
posterior spinal fusion procedures withmultilevel instrumentation, in adults 18 to<86 years of age.

The number of subjects in each vaccine group withpostoperative S aureus SSI occurring within 180 daysof elective open posterior spinal fusion procedureswith multilevel instrumentation.



The number of subjects in each vaccine group withpostoperative ISA disease occurring within 90 days ofelective open posterior spinal fusion procedures withmultilevel instrumentation.

Exploratory Efficacy
 To assess the efficacy of SA4Ag in theprevention of postoperative ISA diseasec
occurring within 90 days of elective open
posterior spinal fusion procedures withmultilevel instrumentation, in adults 18 to<86 years of age.
To assess the efficacy of SA4Ag in theprevention of postoperative ISA disease
occurring within 180 days of elective open
posterior spinal fusion procedures withmultilevel instrumentation, in adults 18 to<86 years of age.

The number of subjects in each vaccine group withpostoperative ISA disease occurring within 180 daysof elective open posterior spinal fusion procedureswith multilevel instrumentation.

To assess the efficacy of SA4Ag in theprevention of postoperative S aureus BSI
and/or deep incisional or organ/space SSI
occurring within 90 days of elective open
posterior spinal fusion procedures with

The number of subjects in each vaccine group withpostoperative S aureus BSI and/or deep incisional ororgan/space SSI occurring within 90 days of elective
open posterior spinal fusion procedures withPFIZER CONFIDENTIAL
Page 3Final Clinical Study Report
Protocol B3451002
CLINICAL STUDY REPORT SYNOPSIS
Table S1. Study Objectives and Endpoints
Objective
multilevel instrumentation, in adults
18 to <86 years of age, based on baseline
S aureus colonization status.
To assess the efficacy of SA4Ag in theprevention of postoperative S aureus BSI
and/or deep incisional or organ/space SSI
occurring within 180 days of elective open
posterior spinal fusion procedures withmultilevel instrumentation, in adults
18 to <86 years of age, based on baseline
S aureus colonization status.

Exploratory Immunogenicity
 To describe the immunogenicity of SA4Ag
in adults aged 18 to <86 years undergoing
elective open posterior spinal fusion
procedures with multilevel
instrumentation.

Exploratory Colonization
 To describe S aureus colonization in adults
aged 18 to <86 years undergoing elective
open posterior spinal fusion procedureswith multilevel instrumentation, before andafter SA4Ag administration.

Exploratory Healthcare-Utilization
 To compare healthcare-utilization data
between vaccine groups.

Endpoint
multilevel instrumentation, based on baseline S aureus
colonization status.
The number of subjects in each vaccine group withpostoperative S aureus BSI and/or deep incisional ororgan/space SSI occurring within 180 days of elective
open posterior spinal fusion procedures withmultilevel instrumentation, based on baseline S aureus
colonization status.

The proportion of subjects at each time point who
achieve specific antibody thresholds in antibody
assays that assess functional activity. These may
include, for example, OPA assays using an S aureus
CP5-expressing strain and a CP8-expressing strain,
and cLIA for ClfA and MntC. Additional exploratory
assays to measure immune responses may also be
conducted on all 4 antigens.

The proportion of subjects at each time point who
achieved specific antibody thresholds to all 4 antigens
both individually and combined using immunologicalassays.

The number of subjects in each vaccine group
determined to be colonized with S aureus on eachoccasion swab samples were collected.

From subjects with S aureus infection, the association
between S aureus strain or strains identified ascolonizing the subject and the S aureus strain or
strains recovered from the infection.



Healthcare-utilization data, including days in hospital,days in an ICU, discharge disposition, inpatient daysin rehabilitation facilities or skilled nursing facility
after discharge, number of hospital readmissions andreoperations, days of antibiotic use, and number of
rehabilitation/physical therapy outpatient visits.

PFIZER CONFIDENTIAL
Page 4

Final Clinical Study Report
Protocol B3451002
CLINICAL STUDY REPORT SYNOPSIS
Table S1. Study Objectives and Endpoints
Objective
Endpoint
Abbreviations: AE = adverse event; BSI = bloodstream infection; ClfA = clumping factor A;
cLIA = competitive Luminex immunoassay; CP5 = capsular polysaccharide serotype 5; CP8 = capsularpolysaccharide serotype 8; EAC = event adjudication committee; ICU = intensive care unit; ISA = invasive
Staphylococcus aureus; MntC = manganese transporter C; OPA = opsonophagocytic activity;
PDI = protocol-defined infection; SAE = serious adverse event; SA4Ag = Staphylococcus aureus 4-antigen
vaccine; SSI = surgical-site infection.
a. BSI: clinical infection involving a recognized pathogen (eg, S aureus) cultured from 1 or more blood
cultures, or a commensal organism cultured from 2 or more blood cultures, whether primary or secondary to
infection at another site.
b. SSI: infection at a surgical incision, whether involving the primary posterior incision or a secondary(eg, anterior) incision associated with the spinal fusion procedure itself or with the harvesting of autologous
bone graft material. SSI was further classified as:
 Superficial SSI: infection involving only skin and subcutaneous tissue of the incision.
 Deep incisional SSI: infection involving deep soft tissues of the incision (eg, fascia and muscle
layers).
 Organ/space SSI: infection involving any part of the body, excluding the skin incision, fascia, ormuscle layers, that was opened or manipulated during the operative procedure. Specific to spinal
fusion surgery, osteomyelitis, vertebral disc space infection, meningitis, and spinal abscess without
meningitis when directly attributable to a surgical incision were classified as organ/space SSIs.
Likewise, intra-abdominal infection, when directly attributable to a secondary anterior intraabdominal incision, and joint and bursa infection, when directly attributable to a surgical incision(eg, harvesting autologous bone), were considered organ/space SSIs.
c. ISA disease: defined as culture of S aureus from a normally sterile location, with clinical evidence ofdisease. With the exception of superficial SSI, all microbiologically confirmed S aureus PDIs wereconsidered ISA disease.

To maintain the scientific integrity, this study used an independent event adjudicationcommittee (EAC) for adjudication of all primary and secondary efficacy endpoints,
exploratory endpoints of invasive S aureus (ISA) disease, multiple-organ failure (MOF)
events, and deaths in accordance with the EAC charter. The EAC’s assessment of these
events represented the final confirmed classification of the event.
The primary and/or secondary efficacy-related events for adjudication included all reported
bloodstream infection (BSI) and surgical-site infection (SSI) events. Furthermore, the EAC
was responsible for adjudicating all other reported protocol-defined infection (PDI) events,
including any other invasive infection (irrespective of the causative pathogen).
METHODS
Study Design:This was a Phase 2b, multicenter, parallel-group, placebo-controlled, randomized,
double-blind study to evaluate Staphylococcus aureus 4-antigen vaccine (SA4Ag) safety andefficacy in the prevention of postoperative S aureus disease in adults aged 18 to <86 years
who were undergoing elective open posterior spinal fusion procedures with multilevel
instrumentation.
PFIZER CONFIDENTIAL
Page 5Final Clinical Study Report
Protocol B3451002
CLINICAL STUDY REPORT SYNOPSIS
This was an event-driven study with a total target of 48 primary endpoint S aureus cases. It
was anticipated that approximately 6000 subjects were to be enrolled globally to accumulatethese 48 cases. However, the total enrollment number could have varied based on theincidence rate of the primary endpoint, true underlying vaccine efficacy (VE), and a potential
early stop for efficacy or futility. The study enrollment was terminated for futility at the timeof the interim analysis after the accrual of 24 per-protocol primary endpoint cases.
There were 5 scheduled study visits and 1 scheduled telephone contact during 6 to 8 monthsof subject participation. Study-eligible subjects who provided consent were randomized in a
1:1 ratio to receive either a single dose of SA4Ag or placebo at Visit 1, which occurred
10 to 60 days prior to undergoing elective open posterior spinal fusion procedures withmultilevel instrumentation (index surgical procedure). Visit 2 was a longitudinal visit andwas to monitor the index hospital admission period from the day of surgery (Day 1) until the
day of hospital discharge. A telephone contact with the subject occurred on Day 21, while
postoperative evaluation study visits occurred on Day 42, Day 90, and Day 180 after surgery.
The Day 180 postoperative evaluation could be conducted by telephone provided that
arrangements were made for blood and colonization sample collection (eg, home nursing
visit).
Unscheduled telephone contacts were conducted for assessment of severe local reactions,severe fever, and severe systemic events after vaccination. Severe fever or a severe local
reaction warranted an unscheduled assessment visit.
Following the index hospital admission, unscheduled visits were conducted for assessment ofsuspected BSI and/or SSI events, and to assess re-hospitalization(s) subsequent to the index
hospital admission.
VE was evaluated by monitoring and assessing the occurrence of PDIs. All BSIs, SSIs, andother ISA infections underwent adjudication by the EAC. Subjects with EAC-confirmed
postoperative S aureus BSI and/or deep incisional or organ/space SSI occurring within
90 days after the index surgical procedure contributed to the primary efficacy endpoint
analysis.
Inclusion/Exclusion Criteria:
Inclusion Criteria
Subjects must have met all of the following inclusion criteria to be eligible for enrollment
into the study:
1. Subjects personally signed and dated the informed consent document indicating that the
subjects had been informed of all pertinent aspects of the study.
2. Subjects were aged 18 to <86 years at the time of enrollment.
PFIZER CONFIDENTIAL
Page 6

Final Clinical Study Report
Protocol B3451002
CLINICAL STUDY REPORT SYNOPSIS
3. Subjects were scheduled to undergo an elective open posterior spinal fusion procedure
with multilevel instrumentation 10 to 60 days after study vaccination.
4. Subjects were available for the entire duration of the study, and were willing and able tocomply with scheduled visits, treatment plan, laboratory tests, and other study
procedures, including completion of the electronic diary (e-diary) for 10 days after study
vaccination (if surgery occurred on Day 10, then the e-diary did not need to be completed
for that day).
5. Subjects were able to be contacted by telephone during study participation.
6. Male subjects and female subjects of childbearing potential and at risk for pregnancy
agreed to use a highly effective method of contraception throughout the study.
Exclusion Criteria
Subjects presenting with any of the following were not included in the study:
1. Planned spinal fusion procedure requiring separate operations performed on separate days(ie, staged procedure).
2. Single-level spinal fusions without insertion of multilevel instrumentation (ie, surgicalimplantation of prosthetic material involving 2 or more motion segments).
3. Surgical indication of malignancy, infection, or acute or emergency trauma (ie, related toa traumatic incident occurring within 6 months prior to study enrollment).
4. History of major surgery (specifically, an open procedure that enters a body cavity,
organ, or joint space) within 3 months prior to enrollment, or anticipated major surgery
other than the index surgical procedure between study enrollment and completion of
study participation.
5. History of any spinal surgery performed within 6 months prior to study enrollment.
6. History of any previous spinal surgery resulting in postoperative BSI or SSI.
7. Congenital or AIDS, or rheumatologic disorder or other illness requiring chronic
treatment with known immunosuppressant medications, including monoclonal antibodies,
within the year prior to enrollment or the use of systemic corticosteroids (equivalent of≥10 mg/day of prednisone) for >14 days within 30 days prior to study enrollment.
8. History of leukemia, lymphoma, or underlying bone marrow disorder (eg,myelodysplasia, myeloma, myeloproliferative disorder) or history of bone marrowtransplant.

PFIZER CONFIDENTIAL
Page 7

Final Clinical Study Report
Protocol B3451002
CLINICAL STUDY REPORT SYNOPSIS
9. Malignancy that required treatment with chemotherapy, immunotherapy, radiation
therapy, or other antineoplastic target therapies within 24 months prior to study
enrollment.
10. Any known or suspected malignancy to the spine.
11. Congenital, functional, or surgical asplenia.
12. End-stage renal disease (defined as requiring or anticipating requirement for
hemodialysis, peritoneal dialysis, or renal transplant) or nephrotic syndrome.
13. Any contraindication to vaccination or vaccine components, including history ofanaphylactic reaction to any vaccine or vaccine-related component.
14. Receipt of blood products or immunoglobulins (including monoclonal antibodies) within
6 months prior to study enrollment OR anticipated receipt of blood products or
immunoglobulins (including monoclonal antibodies) prior to the index hospital
admission.
15. Previous administration of S aureus vaccine or S aureus/Candida vaccine.
16. Antibiotic therapy for microbiologically confirmed ISA disease within 12 months prior toenrollment.
17. Participation in other studies involving investigational drug(s) (Phases 1-4) within
30 days before the current study begins and/or anticipated participation during the study.
18. Pregnant females, breastfeeding females, and males and females of childbearing potential
who were unwilling or unable to use a highly effective method of contraception, for theduration of the study.
19. Presence of a colostomy, urostomy, tracheostomy, percutaneous gastrostomy tube,
indwelling vascular or urinary catheter, central nervous system shunt, central nervous
system implanted device, or spinal cord stimulator; or anticipated presence of acolostomy, urostomy, tracheostomy, percutaneous gastrostomy tube, indwelling vascularor urinary catheter, central nervous system shunt, central nervous system implanted
device, or spinal cord stimulator prior to the index hospital admission.
20. Other severe acute or chronic medical or psychiatric condition (including drug andalcohol dependencies) or laboratory abnormality that increased the risk associated withstudy participation or investigational product administration or may interfere with theinterpretation of study results and, in the judgment of the investigator, would make thesubjects inappropriate for entry into this study.

PFIZER CONFIDENTIAL
Page 8Final Clinical Study Report
Protocol B3451002
CLINICAL STUDY REPORT SYNOPSIS
21. Subjects who were investigational site staff members directly involved in the conduct of
the study and their family members, site staff members otherwise supervised by theinvestigator, or subjects who were Pfizer employees directly involved in the conduct of
the study.
Vaccines Administered:
Study subjects received a single 0.5-mL dose of investigational product (SA4Ag or placebo)
into the deltoid muscle in the nondominant arm at Visit 1. As a standard practice ofvaccination, administration occurred in the nondominant arm unless medicallycontraindicated.
Efficacy Evaluations:
All subjects who underwent the per-protocol or modified intent-to-treat (mITT) surgery
procedure were monitored for any PDI after surgery until the Day 180 postoperativeevaluation. All PDIs that did not constitute primary or secondary endpoints were
simultaneously reported to the EAC and reported as an adverse event (AE)/serious adverse
event (SAE).
Immunogenicity Evaluations:
Blood samples for immunogenicity assessments were collected from all subjects prior tovaccination, prior to the index surgery and at hospital discharge, at each postoperative clinic
visit, and at each unscheduled BSI/SSI assessment visit and unscheduled hospitalization
visits if the subject had MOF. Immunoassays were performed at select time points and may
have included opsonophagocytic activity (OPA) assays using S aureus capsularpolysaccharide serotype 5 (CP5)- and capsular polysaccharide serotype 8 (CP8)-expressing
strains, and competitive Luminex immunoassays (cLIAs) for clumping factor A (ClfA) andmanganese transporter C (MntC). A subset of cases and noncases was tested for
immunogenicity at 3 select time points (day of index surgery, hospital discharge, and Day 90
postoperative evaluation) following the futility analysis.
Colonization Evaluations:
Oropharyngeal and nasal swabs for S aureus colonization were collected from all subjects
prior to study vaccination, as specified at each postvaccination visit, and at each BSI/SSI
assessment visit.
Healthcare-Utilization Evaluations:
Upon hospital discharge following the index hospital admission, for each subsequenthospitalization, and for each postoperative follow-up visit, a healthcare-utilizationassessment was conducted.
PFIZER CONFIDENTIAL
Page 9Final Clinical Study Report
Protocol B3451002
CLINICAL STUDY REPORT SYNOPSIS
Safety Evaluations:Starting on the day of vaccination, local reactions (redness, swelling, and pain at the injectionsite) systemic events (fatigue, headache, vomiting, diarrhea, muscle pain, and joint pain), andfever were recorded in the e-diary for 10 days by the subject. Fever was defined as an oral
temperature of ≥38.0°C (100.4°F) and analyzed as a systemic event.
AEs were collected and analyzed from the day of vaccination until the day of surgery, fromthe day of vaccination until Day 42 postoperative evaluation, from the day of surgery until
Day 42 postoperative evaluation. Newly diagnosed chronic medical disorders (defined as adisease or medical condition, not previously identified, that was expected to be persistent orotherwise long-lasting in its effects) were collected and analyzed from the Day 42
postoperative evaluation until the Day 180 postoperative evaluation. SAEs were collected
and analyzed from vaccination until the day of surgery, from vaccination until the Day 180
postoperative evaluation, and from the day of surgery until the Day 180 postoperativeevaluation.
Preoperative and perioperative subject status were evaluated using:Charlson Comorbidity Index (CCI): a validated prognostic indicator for which factors,
individually or in combination, may increase the risk of short-term mortality for patientsenrolled in longitudinal studies. The sum of the values for each comorbid condition(score range of 1 to 6) was added to the subject’s value for age (score range of 0 to 5) toobtain the CCI. Both the CCI and the Charlson probability (10-year survival) was
derived programmatically.

American Society of Anesthesiologists (ASA) physical status classification system:
utilized by anesthesiologists to assess the fitness of surgical patients prior to undergoing
surgery. The ASA score (scale of 1 [healthy patient] to 5 [moribund patient]) correlateswith patient morbidity and postoperative infection risk.

Organ failure (OF) events were monitored for subjects who underwent the index surgicalprocedure, from after surgery to Day 180, as follows: during the index hospital admission
from after surgery until discharge, and during any subsequent hospitalization(s) that occurred
over the course of the study, including, where possible, those that occurred at any outside
hospital.
A protocol definition for OF was established for each of the 6 organ systems (respiratory,
cardiovascular, renal, hematological, neurological, and hepatic) on the basis of prospective
sequential organ failure assessment (SOFA) scores (range of 0 to 4). OF was defined as a
SOFA score ≥3 for any 1 organ system, while MOF was defined as OF in 2 or more organsystems simultaneously. Each MOF was classified as an AE or SAE and appeared in theappropriate analysis.

PFIZER CONFIDENTIAL
Page 10

Final Clinical Study Report
Protocol B3451002
CLINICAL STUDY REPORT SYNOPSIS
Statistical Methods:
Analysis Populations
Per-Protocol Efficacy Population: The per-protocol efficacy population included subjects
who met all eligibility criteria, were vaccinated as randomized, underwent the index surgery
9 to 90 days (inclusive) after vaccination, underwent surgery consistent with study-defined
criteria for the index surgery, did not have the index surgery modified to be a staged
procedure on separate days, had no major protocol violations before reporting of thesuspected S aureus infection, and had no infection or malignancy identified during the index
surgical procedure. Subjects were analyzed according to the investigational product to which
they were randomized (SA4Ag or placebo).
Modified Intent-to-Treat (mITT) Efficacy Population: The mITT efficacy population
included subjects who were vaccinated and underwent spinal surgery. Subjects wereanalyzed according to the investigational product to which they were randomized (SA4Ag orplacebo).
Restricted Modified Intent-to-Treat (mITT) Efficacy Population: The restricted mITT
efficacy population was a subset of the mITT efficacy population. It excluded subjects witha pre-existing infection, or malignancy, or acute or emergency trauma, at any time fromenrollment up to and including the time of the index surgery.
Safety Population: All subjects who received investigational product were included in thesafety population. Subjects were analyzed according to the investigational product they
actually received.
Modified Intent-to-Treat (mITT) Immunogenicity Population: The mITT immunogenicity
population comprised all subjects who were vaccinated and had at least 1 valid anddeterminate postvaccination immunogenicity result. Subjects were analyzed according to theinvestigational product to which they were randomized.
Modified Intent-to-Treat (mITT) Colonization Population: The mITT colonization population
included all randomized subjects who had at least 1 valid colonization swab sample result.
Methods for Efficacy Endpoint Analysis
Efficacy endpoint evaluations included:
Incidence of postoperative S aureus BSI and/or deep incisional or organ/space SSI
occurring within 90 and 180 days after index surgery.



Incidence of postoperative S aureus SSI occurring within 90 and 180 days after index
surgery.
PFIZER CONFIDENTIAL
Page 11

Final Clinical Study Report
Protocol B3451002
CLINICAL STUDY REPORT SYNOPSIS

Incidence of postoperative ISA disease occurring within 90 and 180 days after index
surgery.

VE was defined as VE = 1 – RR, where RR was the relative risk in SA4Ag compared toplacebo (ie, the proportion of SA4Ag recipients who met the primary endpoint relative to the
proportion of placebo recipients who met the primary endpoint).
A sequential analysis was performed on the primary endpoint for the per-protocol efficacy
population, in which early stopping boundaries were based on a group-sequential design. An
interim analysis was performed after the accrual of 24 cases that met the primary efficacy
endpoint.
There were pre-specified futility checks after approximately 10 and 15 cases had accrued.
Only the primary endpoint was examined. The power of the study to reject the original null
hypothesis, conditional upon the results accumulated so far, was calculated. Futility would
be declared and the study ceased enrollment if the conditional power fell below 20%.
An interim analysis was to be performed after the accrual of 24 cases that met the primary
efficacy endpoint as confirmed by the EAC. Only the primary endpoint was to be examined.
The Data Monitoring Committee (DMC) was to make a recommendation for study
continuation with or without modification unless 1 of the following criteria was fulfilled at
the interim analysis, in which case recommendations may have been made as follows:

Futility criterion was met (ie, conditional power <50%); a recommendation to stop
enrollment for futility may have been made.



Clinically significant efficacy was demonstrated (ie, lower limit of the 99.7% confidence
interval [CI] exceeded 20%); a recommendation to continue the study with modification
to an open label design may have been made.

Methods for Immunogenicity Endpoint Analysis
Immunogenicity endpoint evaluations included:
1. The proportion of subjects who achieved specific antibody thresholds at each scheduled
time point, compiled separately for each antigen/assay.
2. The proportion of subjects who achieved specific antibody thresholds to all 4 antigens
simultaneously at each scheduled time point, limited to CP5/OPA, CP8/OPA, ClfA/cLIA,
and MntC/cLIA.
3. Geometric mean titer (GMT) at each time point.
4. Geometric mean fold rise (GMFR) from Visit 1 to Visit 2 admission.
PFIZER CONFIDENTIAL
Page 12Final Clinical Study Report
Protocol B3451002
CLINICAL STUDY REPORT SYNOPSIS
5. Increases of 2-, 4-, 8-, 16-, and 32-fold from Visit 1 to Visit 2 admission.
Methods for Colonization Endpoint Analysis
Colonization endpoint evaluations, based on colonization results from scheduled visits, were:
1. Colonization, defined as the number and proportion of subjects in each vaccine group
determined to be colonized with S aureus at each scheduled visit where swab samples
were collected.
2. Subject carriage status, characterized across visits as persistent, indeterminate,intermittent, or noncarrier as described below.
Persistent: positive at 4 of 5, 5 of 5, 5 of 6, or 6 of 6 visits.

Indeterminate: 3 or 4 visits, regardless of combination of positive/negative results.

Intermittent: positive at 1 or 2 visits if 2 visits are available, positive at 1 to 3 visits if
5 visits are available, positive at 1 to 4 visits if 6 visits are available.



Noncarrier: no positive results at any visit, minimum of 5 visits.

3. Acquisition, defined as a positive swab at any visit after the index surgery, given that theresults at the time of vaccination and prior to surgery were both negative.
4. Clearance, defined as 2 consecutive postbaseline negative swabs, given that all precedingswabs were positive.
Colonization, carriage status, acquisition, and clearance were compiled for “any S aureus,”
methicillin-resistant S aureus (MRSA), and methicillin-sensitive S aureus (MSSA).
Methods for Healthcare-Utilization Endpoint Analysis
For healthcare utilization endpoint evaluations, variables whose units were days (eg, numberof days in an intensive care unit [ICU]) were summarized by sample size, mean, standard
deviation, median, minimum, and maximum. Categorical variables (eg, interventional
procedures, discharge disposition) were summarized by frequency counts and proportion ofsubjects in each category. The number of service visits and the number of
rehabilitation/physical therapy visits were summarized by sample size, mean, standard
deviation, median, minimum, and maximum.
Methods for Safety Endpoint Analysis
Local reactions and systemic events reported in the e-diary were summarized by the
maximum severity across the 10-day observation period.
PFIZER CONFIDENTIAL
Page 13

Final Clinical Study Report
Protocol B3451002
CLINICAL STUDY REPORT SYNOPSIS
AEs (including newly diagnosed chronic medical disorders from Day 42 until Day 180,
SAEs, and deaths) were summarized by AEs with ≥1% incidence in either vaccine group ineither the preoperative or postoperative period, and by all remaining AEs. For AEs with
≥1% incidence, incidence proportions, the differences between vaccine groups inproportions, and 95% CIs for the differences were provided. For all remaining AEs, only
incidence proportions and the differences between vaccine groups in proportions weresummarized.
Events of MOF were compared across vaccine groups using the using the Fisher exact test,
2-sided, for each organ system.
Methods for Handling of Missing Values
Missing values were not imputed for any immunogenicity, safety, demographic, orcolonization variables. However, immunogenicity values less than the lower limit ofquantitation (LLOQ) were set as 0.5 × LLOQ for the analysis.
RESULTS
Subject Disposition and Demography:
In this event-driven study with a total target of 48 primary endpoint S aureus cases, it was
anticipated that 6000 subjects would be enrolled globally to accumulate these 48 cases.
Upon the DMC interim analysis of the primary endpoint after accrual of 24 primary endpointcases, enrollment in the study was terminated upon the DMC’s recommendation that futility
criteria had been met. A total of 3450 subjects were randomized in the study, with
3417 (99.0%) completing vaccination, 3311 (96.0%) completing index surgery, and3193 (92.6%) completing the study.
Most (3091 [89.6%]) randomized subjects were included in the per-protocol efficacy
population: 1544 (89.5%) in the SA4Ag group and 1547 (89.7%) in the placebo group.
Exclusion from the per-protocol efficacy population was similar for SA4Ag and placebo
subjects (10.4% overall), and most often because the subject did not undergo spinal
surgery (4.0%).
Overall, 55.3% of subjects were female, most (75.5%) were white, and the mean age at
vaccination was 62.7 years (range: 18 to 85 years). Demographics were generally similar
across the SA4Ag and placebo groups.
Overall, comorbidities and physical status for subjects in the safety population weregenerally similar for the SA4Ag and placebo groups at the time of surgery. The vast
majority of subjects in both groups had CCI scores ≤4, with mean scores of 3.4 and 3.5 in the
SA4Ag and placebo groups, respectively, indicating that subjects had limited significant
co-morbidities. The Charlson 10-year survival probabilities were comparable in both groups,
with mean probabilities of 75.5% and 74.4% and median probabilities of 90.1% and77.5% for the SA4Ag and placebo groups, respectively. At the time of surgery,
PFIZER CONFIDENTIAL
Page 14Final Clinical Study Report
Protocol B3451002
CLINICAL STUDY REPORT SYNOPSIS
approximately two-thirds of subjects in both groups had an ASA physical status classificationof 1 or 2, indicating they were assessed to be healthy or had mild systemic disease with nofunctional limitation. The mean observed ASA physical classification status was 2.3 for boththe SA4Ag and placebo groups. No subjects had an ASA physical status classification of
5 (moribund patient likely to die within 24 hours), and 0.9% of all subjects had aclassification of 4 (severe systemic disease that is a constant threat to life).
The characteristics of the index surgeries and related hospitalizations for subjects in the
per-protocol efficacy population were similar for the SA4Ag and placebo groups. Key
characteristics in each group in this surgical population include days from vaccination tosurgery (mean of approximately 23 days), use of decolonization measures(approximately 56%), motion segments fused (mean of approximately 4 motion segments),
surgical duration (mean duration of >250 minutes), blood loss (mean of >600 mL), and unitsof blood products transfused (mean of approximately 4 units of blood products). Almost all
subjects (approximately 97% in each group) received prophylactic antibiotics within 1 hourprior to incision, and approximately 56% in each group received intrawound antibiotics. The
majority of index procedures were initial spinal fusions (>70%) and were performed byorthopedic surgeons (>70%).
The key surgical reoperation characteristics, including motion segments fused, blood loss,
and blood transfusions, were similar in for the SA4Ag and placebo groups in the per-protocol
efficacy population. Subjects may have had multiple indications for reoperations, including
debridement, loose hardware, and decompression. Overall, 66.1% and 67.5% of those in the
SA4Ag and placebo groups, respectively, had “other” reasons, for example other hardware
related issues, wound explorations and infection related reasons. There was evidence of
infection in 29.9% and 34.2% of subjects having a reoperation in the SA4Ag and placebogroups, respectively. Accordingly, a higher proportion of subjects had surgical woundclassifications for reoperations compared with index surgeries that were clean-contaminated,
contaminated, or dirty/infected. Compared to the index surgeries, reoperations were a shorter
duration (mean durations of 148.2 and 129.3 minutes in the SA4Ag and placebo groups,
respectively), had less intraoperative blood loss (mean blood loss of 315.2 mL and 336.8 mL
in the SA4Ag and placebo groups, respectively), and fewer motion segments were fused(mean of 3.6 and 3.2 motion segments fused in the SA4Ag and placebo groups, respectively).
The numbers of subjects in the per-protocol efficacy population readmitted after index
surgery included 206 subjects in the SA4Ag group and 211 subjects in the placebo groupwere readmitted after index surgery. Characteristics of the hospital admissions for subjects
readmitted to the hospital were comparable in the SA4Ag and placebo groups. Readmissions
were related to complications of the index surgery for 46.1% and 41.7% of subjects in the
SA4Ag and placebo groups, respectively. For subjects readmitted for complications of theindex surgery, 69.5% and 75.0% of subjects in the SA4Ag and placebo groups, respectively,
required additional surgery. Durations of readmissions and ICU stays were similar for the
SA4Ag and placebo groups.
PFIZER CONFIDENTIAL
Page 15

Final Clinical Study Report
Protocol B3451002
CLINICAL STUDY REPORT SYNOPSIS
The mean duration of any antibiotic use from the day of index surgery until study completionor withdrawal was similar in the SA4Ag and placebo groups (11.9 and 12.3 days,
respectively) in the mITT efficacy population.
Efficacy Results:

For the primary efficacy analysis, the VE of SA4Ag in the prevention of postoperative
S aureus BSI and/or deep incisional or organ/space SSI within 90 days of the index
surgery was 0.0% (14 of 28 cases in the SA4Ag group and 14 of 28 cases in the placebogroup) with 95% CI of -126.30% to 55.81% in the per-protocol efficacy population. Of
note, the majority of subjects with BSI also had S aureus deep or organ/space SSIs.
There were only 2 additional cases included in the restricted mITT analysis of the
primary efficacy endpoint (both in the placebo group), therefore the overall conclusion of
no VE remains the same. The case split for BSI slightly favored the vaccine in the
per-protocol population, with 7 cases of BSI in the SA4Ag group compared with 11 in
the placebo group (VE = 36.36% [95% CI: -79.76, 79.08%]). This trend was more
prominent in the mITT efficacy population (7 SA4Ag/13 placebo). Of note, the primary
efficacy endpoint infection rate of 0.9% in the placebo group was lower than the
anticipated ~1.4%.



There was only 1 additional deep or organ/space SSI (in the SA4Ag group) reported
between Day 90 and Day 180 in the per-protocol efficacy population; therefore, thesecondary efficacy endpoint through 180 days after index surgery showed similar results
to the primary efficacy endpoint.

The secondary efficacy analysis of S aureus SSI through 90 days after index surgery also
showed no efficacy, with 24 cases of SSI in the SA4Ag group compared with 22 cases in
the placebo group for the per-protocol efficacy population.



Only 2 more cases of S aureus SSI, 1 in each group, were reported between Day 90 and
Day 180 in the per-protocol efficacy population, therefore this additional secondary
endpoint showed similar results as through 90 days after index surgery.



For the 15 and 19 cases of ISA disease occurring in the SA4Ag and placebo groups,
respectively, within 90 days after index surgery, and 1 additional case in the placebogroup occurring between Day 90 and Day 180 (mITT efficacy population), SA4Ag
showed no meaningful efficacy in the prevention of postoperative ISA disease occurring
within 90 or 180 days after index surgery.



For the 14 cases of BSI and/or deep incisional or organ/space SSI occurring in eachgroup within 90 and 180 days after index surgery in the per-protocol efficacy population,
further analysis of cases in the SA4Ag and placebo groups by baseline S aureus
colonization status did not show VE.
PFIZER CONFIDENTIAL
Page 16Final Clinical Study Report
Protocol B3451002
CLINICAL STUDY REPORT SYNOPSIS

Summaries of efficacy by S aureus colonization status, number of motion segments
fused, race, ethnicity, age, sex, smoking status, country, and CCI score were limited bysmall numbers of cases in each group; however, they did not show any trends towards
efficacy.



There was no indication that SA4Ag increased the risk or invasiveness of S aureus
infection or infection of any etiology.

Immunogenicity Results:


SA4Ag elicited substantial functional immune responses to CP5, CP8, ClfA, and MntC at
all time points after vaccination and GMTs were generally similar in cases and noncases.
GMTs generally peaked on the day of index surgery or hospital discharge and thendeclined, but were still at higher levels on the day of hospital discharge and Day 90
compared to the day of vaccination.

On the day of index surgery, the CP5 GMTs for the SA4Ag group were
22,417.1 (95% CI: 13,536.1, 37,125.0) and 22,095.3 (95% CI: 18,858.8, 25,887.4) for
cases and noncases, respectively; for the placebo group, they were 414.3 (95% CI: 256.5,
668.9) and 262.0 (95% CI: 205.9, 333.4) for cases and noncases, respectively. The CP8
GMTs for the SA4Ag group were 18,286.5 (95% CI: 11,221.9, 29,798.6) and
23,281.5 (95% CI: 19,374.9, 27,975.8) for cases and noncases, respectively; for theplacebo group, they were 689.9 (95% CI: 378.6, 1257.3) and 609.2 (95% CI: 449.0,
826.5) for cases and noncases, respectively.

On the day of index surgery, the ClfA GMTs for the SA4Ag group were
2831.4 (95% CI: 1487.5, 5389.3) and 3053.8 (95% CI: 2518.6, 3702.8) for cases andnoncases, respectively; for the placebo group, they were 216.5 (95% CI: 165.5, 283.3)
and 190.7 (95% CI: 163.4, 222.5) for cases and noncases, respectively. The MntC GMTs
for the SA4Ag group were 4231.9 (95% CI: 2468.9, 7253.8) and
2926.1 (95% CI: 2452.3, 3491.5) for cases and noncases, respectively; for the placebogroup, they were 338.6 (95% CI: 242.1, 473.5) and 272.7 (95% CI: 232.7, 319.6) for
cases and noncases, respectively.

The percentage of subjects achieving a ≥4-fold increase in titers from baseline washighest on the day of hospital discharge in the SA4Ag group for both case and noncase
subjects. Overall, on the day of index surgery the majority of both case and noncase
subjects achieved a ≥4-fold increase from baseline in CP5 and CP8 OPA titers (≥91% ofsubjects) and in ClfA and MntC titers (≥73.5% of subjects).

For CP8, on the day of index surgery a lower proportion of cases achieved ≥16-fold rises
in titers (48.1%; 95% CI: 28.7, 68.1%) compared with noncases (72.9%; 95% CI: 58.2,
84.7%). No substantial differences between cases and noncases were observed for theother antigens.
PFIZER CONFIDENTIAL
Page 17

Final Clinical Study Report
Protocol B3451002
CLINICAL STUDY REPORT SYNOPSISOn the day of index surgery the majority (≥73.5%) of SA4Ag subjects (both cases andnoncases) achieved the defined OPA titer thresholds (CP5 ≥1000, CP8 ≥2000) and cLIA
titer thresholds (≥4-fold rise from baseline for MntC and ClfA). For both cases andnoncases, the majority (66.7%) of SA4Ag subjects achieved defined titers for all 4 assays
on the day of index surgery.

Surgical subjects in this study had lower CP5 (estimated ratio 0.5) and CP8 (estimatedratio 0.6) titers than the healthy subjects in previous studies (B3451015 and B3451003).
However, the magnitude of the immune responses in surgical subjects was still high forboth cases and noncases. Also, surgical subjects in this study had comparable titers for
ClfA (estimated ratio 0.9) and MntC (estimated ratio 0.8) relative to the healthy subjects
in previous studies. The results of these analyses for subjects across studies, however,should be interpreted with caution.

Colonization Results:

S aureus colonization rates in either the nose or throat were similar among the SA4Ag
and placebo groups at each visit through Day 180 after index surgery. At baseline (prior
to vaccination), 34.9% and 33.4% of subjects in the SA4Ag and placebo groups,
respectively, were colonized. The proportion colonized decreased through the hospitaldischarge visit but returned close to baseline by the Day 180 visit, with no notabledifferences in the percentage colonized between the SA4Ag and placebo groups.



S aureus colonization was mostly due to MSSA, with 31.1% of all subjects colonizedwith MSSA in the nose or throat at baseline compared with 3.3% colonized with MRSA.

For cases including subjects with adjudication-confirmed S aureus-related SSI and/or
BSI, the majority (63.8%) of all subjects were positive at either site at baseline; fornoncases, 35.8% of all subjects were positive at either site at baseline.

Colonization analysis by age group (18 to <50 years, 50 to <65 years, and 65 to<86 years) was consistent with trends observed in previous studies, with the youngest age
group having the highest proportion of subjects with S aureus colonization at any visit.

Persistent colonization by any S aureus was similar for the SA4Ag (13.1%) andplacebo (15.1%) groups. In both groups, persistent MRSA colonization occurred in≤1% of subjects.

Acquisition of any S aureus was similar for the SA4Ag (11.1%) and placebo (10.1%)
groups.

Conclusions for analyses of colonization by primary endpoint were generally limited by
few subjects meeting the primary endpoint.
PFIZER CONFIDENTIAL
Page 18

Final Clinical Study Report
Protocol B3451002
CLINICAL STUDY REPORT SYNOPSIS
Healthcare-Utilization Results:Overall, healthcare utilization relating to hospitalization, hospital discharge, andoutpatient rehabilitation/physical therapy after index surgery was similar for subjects in
the SA4Ag and placebo groups.



The median duration of index hospitalization was 7.0 days for subjects in both groups.



Readmissions after index surgery occurred in 13.7% and 13.8% of subjects in the SA4Ag
and placebo groups, respectively. Readmissions were related to complications of index
surgery in 46.1% and 40.5% of subjects in the SA4Ag and placebo groups, respectively.
Among subjects with readmissions related to complications of index surgery, an
additional surgery occurred in 69.3% and 75.3% of subjects in the SA4Ag and placebogroups, respectively. The median number of days in the ICU from readmissions due tocomplications of index surgery were 2.0 and 3.0 days in the SA4Ag and placebo groups,
respectively.

Safety Results:Reporting of any local reaction within 10 days after vaccination was significantly morecommon in the SA4Ag group than the placebo group (28.9% compared to 9.8%,
respectively; p < 0.001). Local reactions reported in either group were mostly mild inseverity. In the SA4Ag group, <1% of subjects reported severe redness, severe swelling,or severe pain at the injection site. Pain at the injection site was the most frequently
reported local reaction in both groups.



Reporting of systemic events within 10 days after vaccination was similar in the SA4Ag
and placebo groups (62.3% and 60.4% reported any systemic event, respectively).
Systemic events reported were mostly mild or moderate in severity. Fatigue was themost frequently reported systemic event in both groups, and there were no significant
differences in the percentages of subjects reporting each of the systemic events including
fever. The reported use of antipyretic or pain medication was similar in the
SA4Ag (39.4%) and placebo (38.9%) groups.



There were no substantial differences in the proportion of subjects in either groupreporting any AEs or SAEs from vaccination to day of index surgery or after index
surgery. Overall, 72.2% of subjects reported an AE and 24.3% of subjects reported an
SAE. Of the 1334 SAEs reported, only 2 were considered related to the investigational
product by the investigator (chills and rheumatoid arthritis). The majority of AEs andSAEs were reported after index surgery.



Newly diagnosed chronic medical disorders were reported in 1.7% of subjects in the
SA4Ag group and 2.4% of subjects in the placebo group; none of these were related tothe investigational product.
PFIZER CONFIDENTIAL
Page 19

Final Clinical Study Report
Protocol B3451002
CLINICAL STUDY REPORT SYNOPSIS

Most related AEs were reported from vaccination until day of index surgery (1.2% and0.2% in the SA4Ag and placebo group), the majority of which were from the generaldisorders and administration site conditions system organ class (SOC) for SA4Ag groupsubjects.



A total of 8 (0.2%) subjects (3 SA4Ag group, 5 placebo group) with AEs leading todiscontinuation reported 9 AEs, with only 1 event (rheumatoid arthritis) in the SA4Ag
group being assessed as related by the investigator.

The occurrence of EAC-confirmed MOFs was similar in the SA4Ag and placebo groups:
10 (0.59%) and 9 (0.53%) subjects, respectively.



Deaths were reported in <1% of subjects in either group between vaccination andDay 180: 13 (0.8%) and 10 (0.6%) subjects in the SA4Ag and placebo groups,
respectively. None of the deaths were assessed as related to the investigational product.
Two additional deaths were reported: 1 subject died prior to vaccination and 1 subject
died after completing the study. For the 10 SA4Ag and 9 placebo group subjects with
MOF, there were 7 deaths (5 SA4Ag group, 2 placebo group) including 1 subject in theplacebo group who had a microbiologically-confirmed S aureus infection.

Overall, SA4Ag was well tolerated with an acceptable safety profile in adults undergoing
elective open posterior spinal fusion procedures with multilevel instrumentation.

Conclusions:This was an event-driven study to evaluate SA4Ag safety and efficacy in the prevention of
postoperative S aureus disease in adults undergoing elective open posterior spinal fusion
procedures with multilevel instrumentation. Enrollment in the study was terminated prior to
the accrual of the planned final number of primary endpoint cases based on a scheduledassessment of the prespecified futility criteria by the external DMC, which noted no safetyconcerns in their review of the safety data.
The results of all randomized subjects presented in this report confirm that SA4Ag was safe
and well tolerated. However, despite substantial antibody responses to each vaccine antigen,
SA4Ag was not efficacious in preventing S aureus BSI or deep or organ/space SSI, S aureus
SSI, or other ISA disease in patients undergoing elective orthopedic surgical procedures.

PFIZER CONFIDENTIAL
Page 20